Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,491Price:--
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,491Price:$35.31
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,491Price:$25.30
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-400Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-400Price:$35.31
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:400Price:$25.30
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-12,364Price:--
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,364Price:$35.31
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:12,364Price:$25.30
-
Mar 13, 2024 (filed on Mar 15, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-26,250Price:--
Filings by filing date
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-14,491Price:--
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,491Price:$35.31
-
Mar 21, 2024 (filed on Mar 25, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:14,491Price:$25.30
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-400Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-400Price:$35.31
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:400Price:$25.30
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-12,364Price:--
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,364Price:$35.31
-
Mar 19, 2024 (filed on Mar 21, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:12,364Price:$25.30
-
Mar 13, 2024 (filed on Mar 15, 2024)Insider Name:Bhatt Padmanabh P.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-26,250Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9715 Key West Avenue ROCKVILLE MD 20850 |
Tel: | 1-443-2130505 |
Website: | https://www.supernus.com |
IR: | See website |
Key People | ||
Jack A. Khattar President, Chief Executive Officer, Secretary, Director | Timothy C. Dec Chief Financial Officer, Senior Vice President | Padmanabh P. Bhatt Senior Vice President - Intellectual Property, Chief Scientific Officer |
Tami Tillotson Martin Senior Vice President - Regulatory Affairs | Frank Mottola Senior Vice President - Quality, GMP Operations and Information Technology | Jonathan Rubin Senior Vice President, Chief Medical Officer - Research and Development |
Business Overview |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD. |
Financial Overview |
For the fiscal year ended 31 December 2023, Supernus Pharmaceuticals Inc revenues decreased 9% to $607.5M. Net income decreased 98% to $1.3M. Revenues reflect Net product sales decrease of 12% to $573.9M. Net income also reflects Pharmaceutical segment loss totaling $5.3M vs. income of $46.1M. Basic Earnings per Share excluding Extraordinary Items decreased from $1.13 to $0.02. |
Employees: | 652 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,325M as of Dec 31, 2023 |
Annual revenue (TTM): | $607.52M as of Dec 31, 2023 |
EBITDA (TTM): | $99.83M as of Dec 31, 2023 |
Net annual income (TTM): | $1.32M as of Dec 31, 2023 |
Free cash flow (TTM): | $110.53M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 54,734,956 as of Feb 20, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |